Aktis Oncology

Aktis Oncology is excited to welcome three exceptional talents to our team! 👋 Paul Blanchard joins us as Scientist in the Lead Discovery Team. Paul's passion for discovering proteins for radiopharmaceutical cancer therapeutics aligns perfectly with our mission. When not in the lab, you might find him running, reading, or engaged in a competitive board game. 👋 Ryan Feaver steps in as our new Director of Molecular Pharmacology. With a background in biomedical engineering, Ryan will lead critical assay development for lead optimization. A North Carolina native and avid college basketball fan, Ryan brings a team-sport mentality to drug discovery. He's excited to return to his home state with his family. 👋 Ichiro Matsumura joins as Associate Director, bringing nearly three decades of protein engineering experience. From his postdoc days in Austin to his professorship in Atlanta, Ichiro has consistently pushed the boundaries of biochemistry. An avid cyclist (despite a college accident!), he's as resilient in life as he is innovative in the lab. The wealth of experience, passion, and unique perspectives these individuals bring to Aktis Oncology adds to our growing bench strength. Please join us in giving them a warm welcome! To learn more about our open positions, visit: https://lnkd.in/erWzsAff #NewHires #BioPharma #CancerResearch #AktisOncology #WereHiring

Aktis is pleased to announce the appointment of Akos Czibere MD, PhD, as Chief Medical Officer.   Dr. Czibere brings significant clinical and scientific expertise and leadership capabilities to the role. His broad experience in oncology drug development and regulatory affairs further strengthens our capabilities to deliver our first-in-class Nectin-4-targeted miniprotein radioconjugate.    Learn more: https://lnkd.in/eqN5Ztk4   #biotechnews #oncologyresearch #cancercare #radiopharmaceuticals

At Aktis Oncology, we are proud to be a part of this land of possibilities, where dreams are pursued, and innovation thrives. We remain committed to upholding the principles that our nation was founded upon, while making a positive impact on the communities we serve.   #IndependenceDay #FourthOfJuly 

Celebrating PRIDE together!      Our teams in Boston and RTP recently gathered for a special PRIDE luncheon. We proudly supported LGBTQ+ owned businesses, Basil Tree and Indulge Catering, who provided delicious food for the event.     Thank you to all our employees who joined in this celebration. Together, we support an inclusive workplace for all.     #PrideMonth #Inclusion #LGBTQAllies 

Today we are proud to announce the promotions of four exceptional people within our organization. Join us in congratulating: · Will Blackwell on his promotion to Director, Chemistry · Tatsiana Kosciuk on her promotion to Senior Scientist, Molecular Pharmacology · Marci Copeland on her promotion to Principal Scientist, Molecular Pharmacology · Wai Lau on his promotion to Director, Lead Discovery   We are proud to have such talented individuals as part of our team and look forward to their continued achievements in their new roles. Please join us in celebrating their well-deserved success!   #AktisOncology #GreatPlaceToWorkFor #GreatCompanyCulture #Collaboration #Innovation #Growth #Hiring

Our dynamic team is at the forefront of radiopharmaceutical discovery and development.    If you're excited about pushing boundaries and making a lasting impact, we invite you to explore our open roles: https://lnkd.in/erWzsAff   #Hiring #AktisOncology #GreatPlaceToWorkFor #GreatCompanyCulture #Collaboration #Innovation #Growth

Today, we observe Juneteenth, a pivotal moment in American history that commemorates the end of slavery in the United States. This observance holds profound significance as a symbol of inclusion for all.     We encourage everyone to take this time to learn more about the rich history and enduring impact of Juneteenth by visiting the Smithsonian's National Museum of African American History and Culture's website: https://lnkd.in/gqvPZFF     #Juneteenth #Reflection #Unity #Equality 

Aktis is pleased to announce the appointment of Ken Herrmann, MD, MBA, to the Board of Directors. Ken has been with Aktis since its inception and has already made tremendous impact through his Chairmanship of the Scientific Advisory Board and in his support of the development and advancement of our clinical assets.   Ken’s expertise builds upon Aktis’ vision of extending the benefits of radiopharmaceuticals for patient populations where unmet needs exist.     #biotechnews #oncologyresearch #cancercare #radiopharmaceuticals   

For the second year in a row, Aktis Oncology is certified as a Great Place To Work US!   This recognition reflects our ongoing commitment to fostering an outstanding workplace culture where employees can thrive. From empowering professional growth to promoting work-life balance, we strive to create an environment that brings out the best in our team.   A huge thank you to all our employees for their dedication, passion, and for making Aktis Oncology such a positive place to be. We will continue prioritizing the well-being and success of our fantastic team. After all, our people are the heart of our achievements.   #GreatPlaceToWork #EmployeeAppreciation #WorkplaceCulture

We are pleased to participate in this year’s TD Cowen's 2nd Annual Radiopharmaceutical Innovation Summit is taking place virtually on June 17, 2024, at 9:20 am ET.   Our President and CEO, Matthew Roden, Ph.D., will join a fireside chat discussing new developments within the radiopharmaceutical space.   To learn more: https://lnkd.in/eVKCH88u